Another clinical study was conducted by Cordonnier and coauthors who reported that among 46 MM patients, of whom 36 had had anti-PD1 therapy and the others had target therapy, non-responders had higher levels of circulating ExoPD-L1 [48]. The gene discussed is PDCD1; the disease is Miyoshi myopathy.